AR035867A1 - Una particula semejante a un virus hcv formada por una proteina de envoltura de hcv, un metodo para formar dicha particula, un medicamento que la contiene, una vacuna, un metodo de deteccion, un kit de diagnostico, el uso de cepas de hansenula o saccharomyces para la expresion de una proteina hcv, e - Google Patents
Una particula semejante a un virus hcv formada por una proteina de envoltura de hcv, un metodo para formar dicha particula, un medicamento que la contiene, una vacuna, un metodo de deteccion, un kit de diagnostico, el uso de cepas de hansenula o saccharomyces para la expresion de una proteina hcv, eInfo
- Publication number
- AR035867A1 AR035867A1 ARP020101493A ARP020101493A AR035867A1 AR 035867 A1 AR035867 A1 AR 035867A1 AR P020101493 A ARP020101493 A AR P020101493A AR P020101493 A ARP020101493 A AR P020101493A AR 035867 A1 AR035867 A1 AR 035867A1
- Authority
- AR
- Argentina
- Prior art keywords
- hcv
- protein
- proteins
- expression
- diagnostic kit
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title abstract 6
- 108090000623 proteins and genes Proteins 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 4
- 238000009007 Diagnostic Kit Methods 0.000 title abstract 3
- 239000002245 particle Substances 0.000 title abstract 3
- 241000700605 Viruses Species 0.000 title abstract 2
- 238000001514 detection method Methods 0.000 title abstract 2
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 229940126601 medicinal product Drugs 0.000 title 1
- 235000018102 proteins Nutrition 0.000 abstract 4
- 101710091045 Envelope protein Proteins 0.000 abstract 3
- 101710188315 Protein X Proteins 0.000 abstract 3
- 102100021696 Syncytin-1 Human genes 0.000 abstract 3
- 238000000746 purification Methods 0.000 abstract 3
- 241000235648 Pichia Species 0.000 abstract 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract 2
- 241000235070 Saccharomyces Species 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 208000015181 infectious disease Diseases 0.000 abstract 2
- 238000012544 monitoring process Methods 0.000 abstract 2
- 238000004393 prognosis Methods 0.000 abstract 2
- 206010008909 Chronic Hepatitis Diseases 0.000 abstract 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 abstract 1
- 235000018417 cysteine Nutrition 0.000 abstract 1
- 150000001945 cysteines Chemical class 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000013595 glycosylation Effects 0.000 abstract 1
- 238000006206 glycosylation reaction Methods 0.000 abstract 1
- 208000006454 hepatitis Diseases 0.000 abstract 1
- 238000003018 immunoassay Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 230000002441 reversible effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/18—Togaviridae; Flaviviridae
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24223—Virus like particles [VLP]
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Una partícula semejante a un virus HCV formada por una proteína de envoltura de HCV o una parte de la misma en la cual las cisteínas están químicamente modificadas y en la cual dicha modificación es reversible, un método para formar dicha partícula, un medicamento que la contiene, una vacuna, un método de detección, un kit de diagnóstico, el uso de cepas de Hansenula o Saccharomyces para la expresión de una proteína HCV, el método de purificación de dichas proteínas, el uso de dichas proteínas para la manufactura de un medicamento y/o de un kit de diagnóstico, un inmunoensayo, un vector y un organismo huésped transformado. Está relacionada con el campo general de la expresión de proteínas recombinantes, purificación de proteínas recombinantes, diagnóstico de la infección por HCV, tratamiento profiláctico contra la infección por HCV, y con la prognosis y el monitoreo de la eficacia clínica del tratamiento de un individuo con hepatitis crónica, o la prognosis y el monitoreo de la enfermedad natural. De modo más particular, está relacionada con el uso de levaduras, por extensión cepas de Hansenula o Saccharomyces glicosilación negativa para la expresión eficiente de proteínas de envoltura de HCV que están glicosiladas en su estructura central, los métodos de purificación para estas proteínas y su utilización en varias aplicaciones, tales como el uso en diagnostico, profilaxis o terapéutica de proteínas de envoltura de HCV purificadas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01870088 | 2001-04-24 | ||
| US30560401P | 2001-07-17 | 2001-07-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR035867A1 true AR035867A1 (es) | 2004-07-21 |
Family
ID=34072546
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020101493A AR035867A1 (es) | 2001-04-24 | 2002-04-24 | Una particula semejante a un virus hcv formada por una proteina de envoltura de hcv, un metodo para formar dicha particula, un medicamento que la contiene, una vacuna, un metodo de deteccion, un kit de diagnostico, el uso de cepas de hansenula o saccharomyces para la expresion de una proteina hcv, e |
| ARP020101494A AR035868A1 (es) | 2001-04-24 | 2002-04-24 | Un acido nucleico recombinante que codifica una proteina de un peptido lider de lisozima de ave o equivalente funcional, un vector que lo comprende, una celula huesped, un metodo para producir una proteina de envoltura del hcv o una parte de la misma. |
| ARP020101495A AR035869A1 (es) | 2001-04-24 | 2002-04-24 | Proteinas de la envoltura de hcv glicosiladas en la estructura central, un metodo para producir la proteina de envoltura de hcv aislada, una composicion que la comprende, metodo para detectar la presencia de anticuerpos anti-hcv en una muestra, un kit de diagnostico para detectar la presencia de ant |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020101494A AR035868A1 (es) | 2001-04-24 | 2002-04-24 | Un acido nucleico recombinante que codifica una proteina de un peptido lider de lisozima de ave o equivalente funcional, un vector que lo comprende, una celula huesped, un metodo para producir una proteina de envoltura del hcv o una parte de la misma. |
| ARP020101495A AR035869A1 (es) | 2001-04-24 | 2002-04-24 | Proteinas de la envoltura de hcv glicosiladas en la estructura central, un metodo para producir la proteina de envoltura de hcv aislada, una composicion que la comprende, metodo para detectar la presencia de anticuerpos anti-hcv en una muestra, un kit de diagnostico para detectar la presencia de ant |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US7314925B2 (es) |
| EP (3) | EP1381671A2 (es) |
| JP (2) | JP4261195B2 (es) |
| KR (1) | KR100950104B1 (es) |
| CN (1) | CN1636050A (es) |
| AR (3) | AR035867A1 (es) |
| AU (3) | AU2002257392B2 (es) |
| BR (2) | BR0209034A (es) |
| CA (3) | CA2443781A1 (es) |
| CZ (1) | CZ20032853A3 (es) |
| HU (1) | HUP0303924A2 (es) |
| MX (2) | MXPA03009632A (es) |
| NZ (2) | NZ529019A (es) |
| OA (1) | OA13092A (es) |
| PL (1) | PL366621A1 (es) |
| RU (1) | RU2274643C2 (es) |
| SK (1) | SK13142003A3 (es) |
| WO (3) | WO2002085932A2 (es) |
| YU (1) | YU84103A (es) |
| ZA (3) | ZA200308274B (es) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040185061A1 (en) * | 1994-07-29 | 2004-09-23 | Innogenetics N.V. | Redox reversible HCV proteins with native-like conformation |
| WO2002085932A2 (en) * | 2001-04-24 | 2002-10-31 | Innogenetics N.V. | Constructs and methods for expression of recombinant hcv envelope proteins |
| DE10143490C2 (de) * | 2001-09-05 | 2003-12-11 | Gsf Forschungszentrum Umwelt | Rekombinantes MVA mit der Fähigkeit zur Expression von HCV Struktur-Antigenen |
| AU2003283365A1 (en) * | 2002-11-08 | 2004-06-07 | Innogenetics N.V. | HCV vaccine compositions comprising E1 and NS3 peptides |
| US7439042B2 (en) * | 2002-12-16 | 2008-10-21 | Globeimmune, Inc. | Yeast-based therapeutic for chronic hepatitis C infection |
| JP4371739B2 (ja) * | 2003-09-02 | 2009-11-25 | 株式会社東芝 | シリアルａｔａインタフェースを持つ電子機器及びシリアルａｔａバスのパワーセーブ方法 |
| EP1574517A1 (en) * | 2004-03-09 | 2005-09-14 | Innogenetics N.V. | HCV E1 comprising specific disulfide bridges |
| EP1602664A1 (en) * | 2004-03-08 | 2005-12-07 | Innogenetics N.V. | HCV E1 comprising specific disulfide bridges |
| JP4885476B2 (ja) * | 2004-05-21 | 2012-02-29 | 株式会社日本触媒 | タンパク質及び／又はペプチドの細胞内導入方法 |
| AU2011254055B2 (en) * | 2004-10-18 | 2012-12-20 | Globeimmune, Inc. | Yeast-based therapeutic for chronic hepatitis C infection |
| EP1809773B1 (en) * | 2004-10-18 | 2014-07-16 | Globeimmune, Inc. | Yeast-based therapeutic for chronic hepatitis c infection |
| US20060234360A1 (en) * | 2005-04-13 | 2006-10-19 | Paola Branduardi | Ascorbic acid production from D-glucose in yeast |
| US9216212B2 (en) | 2005-08-05 | 2015-12-22 | University Of Massachusetts | Virus-like particles as vaccines for paramyxovirus |
| US7951384B2 (en) * | 2005-08-05 | 2011-05-31 | University Of Massachusetts | Virus-like particles as vaccines for paramyxovirus |
| PE20070796A1 (es) * | 2005-10-24 | 2007-08-15 | Wyeth Corp | Metodo de produccion proteica utilizando compuestos anti-senescencia |
| CA2651456A1 (en) | 2006-05-19 | 2007-11-29 | Glycofi, Inc. | Recombinant vectors |
| AU2015234338C1 (en) * | 2006-07-28 | 2017-07-20 | The Trustees Of The University Of Pennsylvania | Improved vaccines and methods for using the same |
| EP2061805B1 (en) * | 2006-08-25 | 2020-02-12 | Macfarlane Burnet Institute for Medical Research and Public Health Limited | Recombinant hcv e2 glycoprotein |
| EP2331125A4 (en) | 2008-09-19 | 2013-03-27 | Globeimmune Inc | IMMUNOTHERAPY FOR CHRONIC HEPATITIS C-VIRUS INFECTIONS |
| WO2010039224A2 (en) | 2008-09-30 | 2010-04-08 | University Of Massachusetts Medical School | Respiratory syncytial virus (rsv) sequences for protein expression and vaccines |
| US20100104555A1 (en) * | 2008-10-24 | 2010-04-29 | The Scripps Research Institute | HCV neutralizing epitopes |
| DE102009044224A1 (de) * | 2009-10-09 | 2011-04-28 | PomBio Tech GmbH Starterzentrum der Universität des Saarlandes Campus Geb. A1-1 | Methode zur Produktion von HCV Virus-ähnlichen Partikeln |
| DK2654785T3 (da) | 2010-12-22 | 2019-06-24 | Bayer Ip Gmbh | Forøget immunrespons hos kvægracer |
| US20140155469A1 (en) | 2011-04-19 | 2014-06-05 | The Research Foundation Of State University Of New York | Adeno-associated-virus rep sequences, vectors and viruses |
| US9534039B2 (en) | 2011-05-09 | 2017-01-03 | Ablynx N.V. | Method for the production of immunoglobulin single variable domains |
| MX2016010993A (es) * | 2014-02-28 | 2017-05-01 | Bayer Animal Health Gmbh | Plasmidos inmunoestimuladores. |
| JP2019504638A (ja) * | 2015-11-13 | 2019-02-21 | マメドフ、タルラン | Ｅｎｄｏ ｈとの同時発現によってインビボｎ−脱グルコシル化組換えタンパク質の産生 |
| EP3184642B1 (de) * | 2015-12-22 | 2019-05-08 | bisy e.U. | Hefezelle |
| AU2017332854A1 (en) | 2016-09-21 | 2019-04-11 | The Governors Of The University Of Alberta | Hepatitis C virus immunogenic compositions and methods of use thereof |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4395395A (en) | 1979-05-21 | 1983-07-26 | The United States Of America As Represented By The Department Of Health And Human Services | Detection of non-A, non-B hepatitis associated antigen |
| EP0288198A3 (en) * | 1987-04-20 | 1989-03-29 | Takeda Chemical Industries, Ltd. | Production of peptide |
| US5135854A (en) | 1987-10-29 | 1992-08-04 | Zymogenetics, Inc. | Methods of regulating protein glycosylation |
| US5683864A (en) | 1987-11-18 | 1997-11-04 | Chiron Corporation | Combinations of hepatitis C virus (HCV) antigens for use in immunoassays for anti-HCV antibodies |
| US5350671A (en) | 1987-11-18 | 1994-09-27 | Chiron Corporation | HCV immunoassays employing C domain antigens |
| US5698390A (en) | 1987-11-18 | 1997-12-16 | Chiron Corporation | Hepatitis C immunoassays |
| JP2791418B2 (ja) * | 1987-12-02 | 1998-08-27 | 株式会社ミドリ十字 | 異種蛋白質の製造方法、組換えｄｎａ、形質転換体 |
| NO177065C (no) * | 1988-09-26 | 1995-07-12 | Labofina Sa | Framgangsmåte for framstilling av enzymatisk aktivt humant lysozym |
| US5747239A (en) | 1990-02-16 | 1998-05-05 | United Biomedical, Inc. | Synthetic peptides specific for the detection of antibodies to HCV, diagnosis of HCV infection and preventions thereof as vaccines |
| US5712087A (en) | 1990-04-04 | 1998-01-27 | Chiron Corporation | Immunoassays for anti-HCV antibodies employing combinations of hepatitis C virus (HCV) antigens |
| WO1992001800A1 (en) * | 1990-07-20 | 1992-02-06 | Chiron Corporation | Method for integrative transformation of yeast using dispersed repetitive elements |
| CA2047792C (en) | 1990-07-26 | 2002-07-02 | Chang Y. Wang | Synthetic peptides specific for the detection of antibodies to hcv, diagnosis of hcv infection and prevention thereof as vaccines |
| ES2188583T3 (es) | 1991-06-24 | 2003-07-01 | Chiron Corp | Polipeptidos para el virus de la hepatitis c (hcv). |
| AU4659993A (en) | 1992-07-07 | 1994-01-31 | Merck & Co., Inc. | Vaccine comprising mixed pres1+pres2+s and core particle |
| DK0992580T3 (da) | 1993-11-04 | 2005-07-11 | Innogenetics Nv | Epitoper på human T-celler, som er immundominante for hepatitis C-virus |
| ES2174957T5 (es) * | 1994-07-29 | 2006-12-16 | Innogenetics N.V. | Proteinas purificadas de envoltura de virus de la hepatitis c para uso diagnostico y terapeutico. |
| ZA9610456B (en) * | 1995-12-20 | 1997-06-20 | Novo Nordisk As | N-terminally extended proteins expressed in yeast |
| US5935824A (en) * | 1996-01-31 | 1999-08-10 | Technologene, Inc. | Protein expression system |
| DE69735242T2 (de) * | 1996-12-20 | 2006-09-21 | Novo Nordisk A/S | N-terminal verlängerte proteine exprimiert in hefe |
| AU752131C (en) | 1997-11-06 | 2003-12-04 | Innogenetics N.V. | Multi-mer peptides derived from hepatitis C virus envelope proteins for diagnostic use and vaccination purposes |
| AU2149899A (en) * | 1998-01-23 | 1999-08-09 | Novo Nordisk A/S | Process for making desired polypeptides in yeast |
| TR200003024T2 (tr) | 1998-04-17 | 2000-12-21 | Innogenetics N.V. | İndirgeme ajanlarını kullanarak geliştirilen immünodiagnostik tahliller. |
| NZ508797A (en) * | 1998-06-24 | 2004-02-27 | Innogenetics N | Particles of HCV envelope proteins: use for vaccination |
| CA2387666A1 (en) | 1999-10-27 | 2001-05-03 | Innogenetics N.V. | Redox reversible hcv proteins with native-like conformation |
| WO2002055548A2 (en) | 2001-01-11 | 2002-07-18 | Innogenetics N.V. | Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use |
| WO2002085932A2 (en) * | 2001-04-24 | 2002-10-31 | Innogenetics N.V. | Constructs and methods for expression of recombinant hcv envelope proteins |
| RU2319505C2 (ru) | 2001-12-18 | 2008-03-20 | Иннодженетикс Н.В. | Очищенные оболочечные белки вируса гепатита с для диагностического и терапевтического применения |
| AU2003283365A1 (en) | 2002-11-08 | 2004-06-07 | Innogenetics N.V. | HCV vaccine compositions comprising E1 and NS3 peptides |
-
2002
- 2002-04-24 WO PCT/BE2002/000062 patent/WO2002085932A2/en active IP Right Grant
- 2002-04-24 YU YU84103A patent/YU84103A/sh unknown
- 2002-04-24 BR BR0209034-1A patent/BR0209034A/pt not_active IP Right Cessation
- 2002-04-24 EP EP02764023A patent/EP1381671A2/en not_active Withdrawn
- 2002-04-24 RU RU2003130955/13A patent/RU2274643C2/ru not_active IP Right Cessation
- 2002-04-24 CA CA002443781A patent/CA2443781A1/en not_active Abandoned
- 2002-04-24 CA CA002443740A patent/CA2443740A1/en not_active Abandoned
- 2002-04-24 CZ CZ20032853A patent/CZ20032853A3/cs unknown
- 2002-04-24 JP JP2002583615A patent/JP4261195B2/ja not_active Expired - Fee Related
- 2002-04-24 AR ARP020101493A patent/AR035867A1/es unknown
- 2002-04-24 MX MXPA03009632A patent/MXPA03009632A/es not_active Application Discontinuation
- 2002-04-24 CN CNA028126076A patent/CN1636050A/zh active Pending
- 2002-04-24 NZ NZ529019A patent/NZ529019A/en unknown
- 2002-04-24 US US10/128,587 patent/US7314925B2/en not_active Expired - Fee Related
- 2002-04-24 AR ARP020101494A patent/AR035868A1/es unknown
- 2002-04-24 BR BR0209033-3A patent/BR0209033A/pt not_active IP Right Cessation
- 2002-04-24 EP EP02721875A patent/EP1414942A2/en not_active Withdrawn
- 2002-04-24 MX MXPA03009626A patent/MXPA03009626A/es not_active Application Discontinuation
- 2002-04-24 WO PCT/BE2002/000064 patent/WO2002086101A2/en active IP Right Grant
- 2002-04-24 OA OA1200500194A patent/OA13092A/en unknown
- 2002-04-24 AR ARP020101495A patent/AR035869A1/es unknown
- 2002-04-24 KR KR1020037013778A patent/KR100950104B1/ko not_active IP Right Cessation
- 2002-04-24 AU AU2002257392A patent/AU2002257392B2/en not_active Ceased
- 2002-04-24 WO PCT/BE2002/000063 patent/WO2002086100A2/en active Application Filing
- 2002-04-24 PL PL02366621A patent/PL366621A1/xx not_active Application Discontinuation
- 2002-04-24 AU AU2002252856A patent/AU2002252856A1/en not_active Abandoned
- 2002-04-24 AU AU2002308449A patent/AU2002308449B2/en not_active Ceased
- 2002-04-24 EP EP02727059A patent/EP1417298A2/en not_active Withdrawn
- 2002-04-24 NZ NZ529324A patent/NZ529324A/en unknown
- 2002-04-24 US US10/128,578 patent/US7048930B2/en not_active Expired - Fee Related
- 2002-04-24 US US10/128,590 patent/US7238356B2/en not_active Expired - Fee Related
- 2002-04-24 HU HU0303924A patent/HUP0303924A2/hu unknown
- 2002-04-24 JP JP2002583616A patent/JP4173741B2/ja not_active Expired - Fee Related
- 2002-04-24 SK SK1314-2003A patent/SK13142003A3/sk unknown
- 2002-04-24 CA CA002444006A patent/CA2444006A1/en not_active Abandoned
-
2003
- 2003-10-23 ZA ZA200308274A patent/ZA200308274B/en unknown
- 2003-10-23 ZA ZA200308272A patent/ZA200308272B/en unknown
- 2003-10-23 ZA ZA200308277A patent/ZA200308277B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR035867A1 (es) | Una particula semejante a un virus hcv formada por una proteina de envoltura de hcv, un metodo para formar dicha particula, un medicamento que la contiene, una vacuna, un metodo de deteccion, un kit de diagnostico, el uso de cepas de hansenula o saccharomyces para la expresion de una proteina hcv, e | |
| Heron et al. | HIV infection and compromised mucosal immunity: oral manifestations and systemic inflammation | |
| Kameyoshi et al. | Cytokine RANTES released by thrombin-stimulated platelets is a potent attractant for human eosinophils. | |
| NL193085C (nl) | Werkwijze voor de winning van humaan leucocyten-interferon, alsmede farmaceutisch preparaat met het aldus verkregen interferon. | |
| NO20045521L (no) | Diarylureaderivater anvendelige for behandling av proteinkinaseavhengige sykdommer | |
| WO2004003143A3 (en) | Viruses and virus-like particles for multiple antigen and target display | |
| WO2005020889A3 (en) | Functional influenza virus-like particles (vlps) | |
| DE60239394D1 (de) | Onkolytische virustherapie | |
| JP2006020648A5 (es) | ||
| ATE365749T1 (de) | Humane peptide/proteine, die das töten von zellen,einschliesslich lymphoide tumorzellen, herbeiführen oder bewirken | |
| CY1107050T1 (el) | Αγωγη κυανοκοβαλαμινης (βιταμινη β12) σε αλλepγικη νοσο | |
| JP2005526085A5 (es) | ||
| JP2018516867A5 (es) | ||
| Lim | ProThera Biologics, Inc.: a novel immunomodulator and biomarker for life-threatening diseases | |
| ATE465753T1 (de) | Zusammensetzungen und verfahren zurbehandlung von krankheiten, die durch das humane papillomavirus vermitteltwerden | |
| Khongphatthanayothin et al. | Serum levels of sICAM-1 and sE-selectin in patients with dengue virus infection | |
| ATE395602T1 (de) | Verwendung von hmgb-proteinen und dafür codierenden nukleinsäuren | |
| ATE338819T1 (de) | Antigenes protein aus malassezia | |
| TW200509964A (en) | VP1 of foot-and-mouth disease virus | |
| CY1112440T1 (el) | Απογλυκοζυλιωμενη και αποσιαλιδωμενη μακρα πεντραξινη ρτχ3 | |
| CN110540585B (zh) | 一种具有改善脑缺血缺氧的蝎子毒素活性多肽HsTx1及其制备方法与应用 | |
| JP2006505536A5 (es) | ||
| RU2459622C1 (ru) | Способ профилактики бронхиальной астмы у детей с рецидивирующим обструктивным бронхитом в условиях повышенной контаминации биосред тяжелыми металлами и альдегидами | |
| Baehr et al. | A diffuse disease of the peripheral circulation (usually associated with lupus erythematosus and endocarditis) | |
| AR032240A1 (es) | Una composicion de vacuna profilactica y terapeutica que comprenden proteinas de envoltura purificadas de virus de hepatitis c |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |